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the model is robust to a wide range of parameter estimates. CONCLUSIONS: This
analysis suggests that the use of ATVRTV in the Mexican healthcare setting is a
preferred option when compared to LPVRTV for treatment of treatment-naïve
HIV patients.
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OBJECTIVES: To examine the incremental cost-effectiveness of palivizumab vs. no
prophylaxis among 3 groups of preterm infants in a Medicaid population. Infants
were6months of age at the start of the RSV season: 1)32 weeks gestational age
(wGA); 2) High-risk (HR) 32–35 wGA ( 2 risk factors) or 3) Low-risk (LR) 32–35 wGA
(1 risk factor). METHODS: We conducted a cost-utility analysis of palivizumab
from a societal perspective based on 5 monthly doses throughout the RSV season.
Medicaid-related inputs included the background rates of RSV disease, marginal
healthcare costs within the first two years of life between infants with RSV com-
pared to controls, and the estimated public payer dollars spent for palivizumab.
The base case included recurrent wheezing (RW), which was excluded during sen-
sitivity analysis.We report the incremental cost-effectiveness ratio (ICER), morbid-
ity, and mortality between the prophylaxed and non-prophylaxed groups.
RESULTS: Prophylaxis among 32 wGA infants was dominant, with and without
RW. For HR 32-35 wGA infants, the ICER was $3,791/QALY with RW and $26,290/
QALY without RW. For LR 32-35 wGA infants, the ICER was $22,690/QALY with RW
and $231,784/QALY without RW. Compared with infants without prophylaxis, in-
fants receiving prophylaxis were projected to have fewer RSV hospitalizations
(-4214 among 32 wGA, 4734 among HR 32-35 wGA, and 1289 among LR 32-35
wGA infants) among the estimated 119,500 premature births inMedicaid in the US.
Likewise, prophylaxis was estimated to reduce the number of deaths by 42 among
32 wGA, 74 among HR 32-35wGA and 20 among LR 32-35 wGA infants.
CONCLUSIONS: Palivizumab was shown to be highly cost-effective among infants
32 wGA and HR 32-35 wGA due to Medicaid’s lower cost structure for healthcare
items and services and higher rates of disease compared to private plans. The
study was sponsored by MedImmune, LLC.
PIN25
COST-EFFECTIVENESS ANALYSIS OF THE INTRODUCTION OF THE VARICELLA
VACCINE IN COLOMBIA
De la Hoz F1, Alvis N2, Gamboa O1, Castañeda C1, Paternina A2
1Universidad Nacional de Colombia, Bogota, D.C., Colombia, 2Universidad de Cartagena,
Cartagena de Indias, Bolívar, Colombia
OBJECTIVES: To perform a cost-effectiveness analysis of the introduction of the
varicella vaccine in theNational Immunization Programof Colombia.METHODS:A
decision analysis model was built to follow two cohorts from birth. One cohort had
vaccination, and the other did not. The time horizon was 30 years. The perspective
was from the third payer. Amicro-costing assessment of varicella in Colombia was
undertaken. All costs were expressed in 2008 dollars of December 31. Incremental
cost-effectiveness ratio (ICER) was the main outcomemeasure. A discount rate for
health benefits and costs of 3%was used. A sensitivity analysis wasmade to assess
assumptions uncertainty. RESULTS: Vaccination would avoid 9,415,444 consulta-
tions, 17,576 hospitalizations, and 1,144 varicella deaths. Cost per Life-Year Gained
(LYG) was US$2,527/LYG. From the third payer perspective in Colombia, varicella
costs without vaccination would be US$88 millions, and with vaccination US$35
million. The sensitivity analysis shows that the vaccination strategy is not cost-
effective if vaccination cost per dose is higher than US$15.6. In the case of a booster
dose every ten years, the vaccinationwould not be cost-effective if vaccination cost
per dose is higher than US$9.8. CONCLUSIONS: Varicella vaccination is highly
cost-effective according toWorld Health Organization criteria (less than per capita
gross domestic product). The authors recommend, weighting the budget impact,
the implementation of the varicella vaccine in Colombia.
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OBJECTIVES: The recent increase of methicillin-resistant S. aureus (MRSA) as the
leading cause of bacteremia, and subsequent infective endocarditis, has led clini-
cians to resort to alternative treatments, rather than the traditional penicillin-
based treatment strategy. Such alternatives include daptomycin,whichhas proven
to be efficacious. An economic evaluation was performed to determine the most
cost-effective alternative between daptomycin and vancomycin for the treatment
of patients with MRSA bacteremia and infective endocarditis. METHODS: A cost-
effectiveness analysis was performed from an institutional perspective (Mexican
Institute of Social Security, IMSS). Vancomycin is currently the treatment of choice
for infective endocarditis within the treatment guidelines; daptomycin is regarded
as an alternative treatment. Effectiveness and safety data was taken from pub-
lished literature; effectiveness parameters included clinical and bacteriological
cure, and safety parameters included drug-related adverse events. Resource use
data was obtained from the institution; total direct costs of hospitalization and
treatment were considered. The source of the unit costs was the institution, cur-
rent for 2010. All costs are expressed in local currency (Mexican Pesos, MXP). The
time horizon was less than 1 year; no discount rate was used. A decision tree was
built with three possible outcomes considered: success or failure to treatment, and
death. A probabilistic sensitivity analysis was performed through a Monte Carlo
simulation with 100,000 iterations to confirm the robustness of the model.
RESULTS: The results show a cost/effectiveness ratio of $371,813.80 MXP for dap-
tomycin compared to $466,229.23MXP for vancomycin,making daptomycin amore
cost-effective alternative (dominant) for the treatment of bacteremia and infective
endocarditis. CONCLUSIONS: From an institutional perspective in Mexico, dapto-
mycin is a more cost-effective (dominant) alternative than vancomycin for the
treatment of bacteremia and infective endocarditis in patients with MRSA infec-
tion.
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OBJECTIVES: The loss of vaccine-induced immunity to pertussis over ten years
after administered increment the burden of pertussis-related disease. To diminish
the burden of pertussis-related disease on children under-5 years we propose a
cost-effectiveness analysis of the introduction of pertussis vaccine in Colombian
adolescents. METHODS: Two cohorts (with vaccinated and unvaccinated adoles-
cents) of childrenwere followed from birth to 5 years (both vaccinatedwith current
scheme: 2-4-6-18 months and 5 years with DTwP). A decision model was used to
estimate the burden of pertussis-related disease. The cost of pertussis was taken
from a previous study. A government perspective was used. Vaccine administra-
tion cost plus vaccine price were assumed between US$5-US$12 per dose. Adoles-
cent vaccination coveragewasassumed tobe 70%.Adeterministic sensitivity analysis
was performed. Costs were US dollars from 2008. RESULTS: Without adolescents
vaccination, the current scheme reduce 93% pertussis cases (from 102,196 to 6,912),
83% deaths (from 408 to 55), and 93% DALYs (18,189 to 1,233). With adolescent
vaccination, cases would reduce from 6,912 to 4,838, deaths from 408 to 39, and
DALYs from 1,233 to 860, in the current scenario. Total pertussis costs without
adolescent vaccination is US$737,186, andwith vaccination US$516,030. Incremen-
tal Cost-Effectiveness Ratiowith a vaccination coverage of 70%would go from4,188
(vaccination cost per dose: US$5) to 10,331 (vaccination cost per dose: US$12).
CONCLUSIONS: This is the first study in a developing country that assesses per-
tussis vaccination in adolescent. Pertussis adolescent vaccination was cost-effec-
tive in Colombia, according to World Health Organization criteria (less than three
times the per-capita Gross Domestic Product). The investigators recommend ado-
lescents pertussis vaccination in Colombia.
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OBJECTIVES: The quadrivalent (6,11,16,18) HPV vaccine has been approved in Bra-
zil for prevention of cervical cancer, vulvar/vaginal pre-cancers, and genital warts
in women age 9 to 26 years. We assessed the health and economic impact of the
quadrivalent (6,11,16,18) HPV vaccine from the healthcare system perspective in
Brazil.METHODS: A publishedmathematical model of the transmission dynamics
of HPV infection and disease was adapted for Brazil. Model inputs were used from
Brazil or the Latin/America region when available; otherwise, the default values in
the original model were used. Maintaining current cervical cancer screening prac-
tices in Brazil, we evaluated two strategies: routine vaccination of females by age 12
(S1), and S1 combined with a temporary (5 years) female catch-up program for age
12–24 years (S2). The vaccine coverage rates were 85% for the routine and 50% for
the catch-up vaccination programs. RESULTS: The most effective strategy was S2.
Comparing S2 to no vaccination, we estimated the cumulative percent reduction in
incident HPV 6/11/16/18-related genital warts-female, genital warts-male, cervical
intraepithelial neoplasia (CIN) grade 1, CIN 2/3, and cervical cancer cases would be
81%, 57%, 70%, 72%, and 59%, respectively over 100 years. The cost-effectiveness
ratios were Brazil Reals 1,203 (US$ 699) per quality-adjusted life years (QALY)
gained for S1 compared with no vaccination, and Brazil Reals 1,522 (US$ 885) per
QALY gained for S2 compared with S1. CONCLUSIONS: In Brazil, vaccination of
females age 12–24 years with a quadrivalent (6,11,16,18) HPV vaccine can reduce
the incidence of cervical cancer, CIN, and genital warts at a cost per QALY ratio
within the range typically regarded by the World Health Organization as cost-
effective.
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OBJECTIVES: The incidence of skin and soft tissue infections (SSTI) has augmented
recently in Mexico, mainly due to increases in vancomycin-resistant pathogens
and immunocompromised patients. New antibiotics, such as daptomycin, have
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proved to be efficacious in the management of SSTI. An economic evaluation was
performed to determine the most cost-effective alternative between daptomycin
and linezolid for the treatment of SSTI with failure to vancomycin therapy.
METHODS: A cost-effectiveness analysis was performed from an institutional per-
spective (Mexican Institute of Social Security, IMSS). Both drugs are includedwithin
the treatment guidelines as secondary therapy for SSTI following vancomycin fail-
ure. As required per guidelines, use of concomitant therapy with ciprofloxacin and
metronidazole was also considered. Effectiveness and safety data was taken from
published literature; effectiveness parameters included clinical and microbiologi-
cal cure, and safety parameters includeddrug-related adverse events. Resource use
data was obtained from the institution; total direct costs of hospitalization and
treatment were considered. The source of the unit costs was the institution, cur-
rent for 2010. All costs are expressed in local currency (Mexican Pesos, MXP). The
time horizon was less than 1 year; no discount rate was used. A decision tree was
built, considering two possible outcomes: success and failure to treatment. A prob-
abilistic sensitivity analysis was performed through aMonte Carlo simulationwith
100,000 iterations to confirm the robustness of the model. RESULTS: The results
show a cost/effectiveness ratio of $52,135.67 MXP for daptomycin compared to
$67,623.14 MXP for linezolid, making daptomycin a more cost-effective alternative
(dominant) for the treatment of SSTI. The sensitivity analysis confirmed the ro-
bustness of the model. CONCLUSIONS: From an institutional perspective in Mex-
ico, daptomycin is a more cost-effective (dominant) alternative than linezolid for
the treatment of SSTI in patients that failed treatment with vancomycin.
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OBJECTIVES: To evaluate the cost effectiveness analysis of Efavirenz/Emtricit-
abine/Tenofovir ((TDFFTCEFV) in naïve patientswithHIV from the public health
system Mexican perspective. METHODS: A decision tree model was developed to
estimate the efficacy and expected value of direct medical costs. Efficacy wasmea-
sured by the percentage of individuals with plasma HIV RNA  50 copies/mL and
and 400 copies/mL. at 96 weeks, based on a systematic review andmeta-analysis
of clinical trials of regimens in treatment-naïve populations. Model follows the
recommendations of antiretroviral persons handling Guide with HIV in Mexico
(2009 SSA). The direct costs and treatment of adverse events in the treatment of
HIV were estimated. When the patient failure, the cost of new treatment was
added. The unitary costs were obtained from the Mexican public health institu-
tions. All costs were calculated in 2010 Mexican Pesos (MXP). Incremental-cost-
effectiveness-ratios were expressed as cost per 1% of individuals with plasma HIV
RNA  50 copies/mL and and  400 copies/mL Costs and outcomes were dis-
counted at 5%. Probabilistic sensitivity analyses via Monte Carlo simulations were
undertaken to incorporate likely distributional properties of key model. RESULTS:
EFVFTCTDF was most effective than others comparators with probability of
0.734 (CI95%:0.601-0.835; n514) -except when compare with TDF/FTC  ATV/r
with efficacy of 0.743 CI95%:0.700-0.786; n440- and 0.746 (0.686-0.798; n232) of
having 50 or 400 RNA copies/ml respectively at 96 weeks, EFVFTCTDF re-
sulted as the alternative with less unitary average total cost ($60,026.00 MX and
$60,122.00, respectively). TDF/FTC/EFV combination is a dominant option and cost
saving compared to alternatives, except TDF/FTC  ATV/r (cost per 1% of individ-
uals with plasma HIV RNA  50 copies/mL of $8,490,581).Deterministic and prob-
abilistic sensitivity analysis showed that the findings are robust. CONCLUSIONS:
Efavirenz/Emtricitabine/Tenofovir is a cost effective drug on 96weeks for the treat-
ment of adult naïve patients with HIV infection in Mexico.
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OBJECTIVES: This study predicted and analyzed outcomes among six options (uni-
versal antiviral therapy without testing [Universal], empiric therapy without test-
ing [Empiric], empiric therapy with lab testing [Empiric_Lab], treatments respond-
ing to lab results [Standard], treatments responding to point-of-care testing [POCT]
results and no treatment [NoTx]) in healthy adults with influenza-like symptoms
who visit physicians within or beyond 48 hours of the onset of symptoms.
METHODS: A decision model was created to predict total and direct medical costs,
symptom-free days, quality of life and days of work lost within 14 days from the
perspective of patients. Most model inputs were derived from the literature; some
were obtained from internal data and expert opinions. Total costs (in $2009 USD)
included costs associated with prescriptions/OTC, tests, complications, hospital-
ization and work-day loss. Cost-effectiveness analysis, cost-utility analysis and
probabilistic sensitivity analysis were performed. RESULTS: Total costs per symp-
tom-free day were $119 ($874/7.3), $130 ($893/6.9), $163 ($1,086/6.7), $162 ($1,103/
6.8), $189 ($1,117/5.9) and $280 ($1117/4.2) for Universal, NoTx, Standard, POCT,
Emiric_Lab and Empiric, respectively. Total costs per quality of lifewere $1,560 ($874/
0.56), $1,641 ($893/0.54), $2,156 ($1,086/0.50), $1,949 ($1,103/0.57), $1,993 ($1,117/0.56)
and $2,195 ($1117/0.54) for Universal, NoTx, Standard, POCT, Emiric_Lab and Empiric,
respectively. Direct medical costs were $238, $169, $380, $336, $358 and $193 for Uni-
versal, NoTx, Standard, POCT, Emiric_Lab and Empiric, respectively. Direct medical
costs per symptom-free daywere $46, $25, $57, $49, $60 and $$46 for Universal, NoTx,
Standard, POCT, Emiric_LabandEmpiric, respectively.Directmedical costsperquality
of lifewere $425, $311, $755, $594, $639and$$360 forUniversal,NoTx, Standard, POCT,
Emiric_Lab and Empiric, respectively. Sensitivity analysis indicated the study results
were robust.CONCLUSIONS:With consideration of total costs, the universal option
was themost cost-effective option.With consideration of directmedical costs only,
no treatment is the most cost-effective option.
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OBJECTIVES:Antiretroviral combinations have been successful in delaying human
immunodeficiency virus (HIV) progression; however, drug resistance may occur.
Maraviroc and enfuvirtide are two drugs currently used in treatment-experienced
HIV patients. The objective was to determine the economic impact of maraviroc
versus enfuvirtide in HIV patients previously treated with conventional
antiretrovirals.METHODS:AMarkovmodelwas developed to assess the economic
consequences of the targeted therapies. The type of analysis was cost-minimiza-
tion based on the premise of clinical equivalence. The clinical outcome used to
support the clinical assumption was the odds ratio of decreasing1.0 log10 viral
copies/ml over placebo. Targeted populationwas composed of adults infectedwith
HIV virus (CCR5 co-receptor tropism), who underwent previous anti-HIV treat-
ments and proved therapeutic failure. Model input data derived from a previously
observed cohort of HIV patients in Brazil. A lifetime horizon was used. The eco-
nomic perspectivewas that of the BrazilianMinistry of Health (MoH) as a payer and
provider of medical services, treatments, and healthcare to its beneficiaries. Costs
were expressed in 2010 Brazilian Currency (1BRL0.59USD). Univariate and multi-
variate (Monte Carlo) analyses tested model robustness. RESULTS: An indirect
comparison between the interventions showed that the effects of the drugs over
placebo was similar from a clinical (odds ratios with approximate values) and
statistical (overlapping confidence intervals) standpoints. Thus, clinical equiva-
lence between the drugs was assumed. The economic analysis showed that the
total cost of anti-HIV treatment per patient with maraviroc was approximately
BRL17 thousand lower than enfuvirtide. Probabilistic sensitivity analysis reported
87% chance of having reduced treatment costs by choosing maraviroc over
enfuvirtide. CONCLUSIONS: The use of maraviroc in treatment-experienced HIV
patients showed to be beneficial for the Brazilian MoH in reducing the economic
burden of the disease. The estimated annual budget impact ranged between BRL
8.0 to 10.5 million favorable to cost reduction.
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OBJECTIVES:Raltegravir, an integrase inhibitor ofHIV-1, is approved for use in both
treatment naïve and treatment experienced HIV-1 infected patients. In Sweden,
raltegravir is reimbursed for patients with documented drug resistance and used
predominately in heavily treated experienced patients. This study aims to inves-
tigate the cost-effectiveness of using raltegravir in treatment naïve patients versus
using raltegravir as a salvage treatment.METHODS:A three-stage continuous-time
Markovmodel representing successive HIV therapies was developed to predict the
costs and quality-adjusted life years (QALYs) over a 50-year time horizon. Patients
progressed to the next stage in themodel as they failed or discontinued the current
therapy for toxicity reasons. In each stage patientsmoved between 18 health states
based on CD4 and HIV RNA levels. At anytime patients could die, suffer coronary
heart disease or develop acquired immunodeficiency syndrome (AIDS). Initiation
on a raltegravir-based regimen was evaluated versus initiation on a protease in-
hibitor (PI)-based regimen. During the second stage patients received a non-nucle-
oside reverse transcriptase inhibitor based regimen. Patients initiating on raltegra-
vir progressing to the third stage received optimized salvage therapy (OT) whereas
patients initiating on a PI received OT plus raltegravir. Data on effectiveness was
gathered from randomized clinical trials and an HIV/AIDS database. Utilities and
health care resource usewere gathered from the literature and adapted to Swedish
situation using expert opinion. RESULTS: Raltegravir-initiating treatment strategy
offered longer undiscounted life expectancy compared to PI initiating strategy
[20.51 vs. 18.60 years]. The incremental cost-utility ratio for using raltegravir in
treatment naïve patients versus using raltegravir as a salvage treatmentwas 85 182
SEK per QALY ($12,564/QALY). Results were sensitive to analytical time horizon.
CONCLUSIONS: Given the data and methods used, the model suggests that using
raltegravir in treatment naïve patients compared to using raltegravir as a salvage
therapy is cost-effective.
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INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED
(TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS: A CANADIAN
COST EFFECTIVENESS ANALYSIS
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1PATH Research Institute, McMaster University, Hamilton, ON, Canada, 2PATH Research
Institute, Hamilton, ON, Canada, 3McMaster University, Hamilton, ON, Canada
OBJECTIVES: Although influenza affects all age groups, influenza is common in
children. Between 15% and 42% of preschool and school-aged children experience
influenza each season. Recently, LAIV has been approved in Canada for use in
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